Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices 11531 

B. Federal Reserve Bank of Kansas 

City (Dennis Denney, Assistant Vice 

President) 1 Memorial Drive, Kansas 

City, Missouri 64198–0001: 

1. Lance L. White, as co-trustee of the 

Lance L. White Revocable Trust and as 

trustee of the Lance L. White Irrevocable 

Trust, and Cherlyn D. White, as trustee 

of the Cherlyn D. White-Conklin 

Irrevocable Trust and as co-trustee of 

the Cherlyn White-Conklin Trust, all of 

Wamego, Kansas; and Monte W. White, 

individually, and as trustee of the MWW 

Irrevocable Trust #1, both of Salina, 

Kansas; as members of the White Family 

Group, a group acting in concert, to 

retain voting shares of Wamego 

Bancshares, Inc., and thereby indirectly 

retain voting shares of Bank of the Flint 

Hills, both of Wamego, Kansas. 

Additionally, Kara L. White, as cotrustee of the Lance L. White Revocable 

Trust, Cherlyn White-Conklin Trust, 

Erich Conklin, as co-trustee, and certain 

minor children, all of Salina and 

Wamego, Kansas; to join the White 

Family Group, and retain voting shares 

of Wamego Bancshares, Inc., and 

thereby indirectly retain voting shares of 

Bank of the Flint Hills. 

Board of Governors of the Federal Reserve 

System, February 19, 2021. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2021–03841 Filed 2–24–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2021–0021] 

Advisory Committee on Immunization 

Practices (ACIP) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public. Time will be available for public 

comment. The meeting will be webcast 

live via the World Wide Web. 

DATES: The meeting will be held on 

February 28, 2021–March 1, 2021, from 

10:00 a.m. to 5:00 p.m. EDT (times 

subject to change). Written comments 

must be received on or before March 1, 

2021. 

ADDRESSES: For more information on 

ACIP please visit the ACIP website: 

http://www.cdc.gov/vaccines/acip/ 

index.html. 

You may submit comments, identified 

by Docket No. CDC–2021–0021 by any 

of the following methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Docket No. CDC–2021–0021, 

c/o Attn: ACIP Meeting, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H24–8, Atlanta, 

GA 30329–4027. 

Instructions: All submissions received 

must include the Agency name and 

Docket Number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

Written public comments submitted 

24 hours prior to the ACIP meeting will 

be provided to ACIP members before the 

meeting. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, Centers for 

Disease Control and Prevention, 

National Center for Immunization and 

Respiratory Diseases, 1600 Clifton Road 

NE, MS–H24–8, Atlanta, GA 30329– 

4027; Telephone: 404–639–8367; Email: 

ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 41 CFR 102–3.150(b), 

less than 15 calendar days notice is 

being given for this meeting due to the 

exceptional circumstances of the 

COVID–19 pandemic and rapidly 

evolving COVID–19 vaccine 

development and regulatory processes. 

The Secretary of Health and Human 

Services has determined that COVID–19 

is a Public Health Emergency. 

Purpose: The committee is charged 

with advising the Director, CDC, on the 

use of immunizing agents. In addition, 

under 42 U.S.C. 1396s, the committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children (VFC) program, 

along with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under provisions of the Affordable Care 

Act, section 2713 of the Public Health 

Service Act, immunization 

recommendations of the ACIP that have 

been approved by the Director of the 

Centers for Disease Control and 

Prevention and appear on CDC 

immunization schedules must be 

covered by applicable health plans. 

Matters To Be Considered: The agenda 

will include discussions on COVID–19 

vaccines. A recommendation vote is 

scheduled. Agenda items are subject to 

change as priorities dictate. For more 

information on the meeting agenda visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/meetings-info.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web; for more information on ACIP 

please visit the ACIP website: http://

www.cdc.gov/vaccines/acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials are part of 

the public record and are subject to 

public disclosure. Do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

CDC does not accept comment by email. 

Written Public Comment: Written 

comments must be received on or before 

March 1, 2021. Oral Public Comment: 

This meeting will include time for 

members of the public to make an oral 

comment. Oral public comment will 

occur before any scheduled votes 

including all votes relevant to the 

ACIP’s Affordable Care Act and 

Vaccines for Children Program roles. 

Priority will be given to individuals 

who submit a request to make an oral 

public comment before the meeting 

according to the procedures below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the February 28, 

2021–March 1, 2021 ACIP meeting must 

submit a request at http://www.cdc.gov/ 

vaccines/acip/meetings/ no later than 

11:59 p.m., EDT, February 25, 2021 

according to the instructions provided. 

11532 Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by February 26, 2021. To accommodate 

the significant interest in participation 

in the oral public comment session of 

ACIP meetings, each speaker will be 

limited to 3 minutes, and each speaker 

may only speak once per meeting. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–03959 Filed 2–23–21; 11:15 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–21–21DC; Docket No. CDC–2021– 

0012] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled ‘National Syringe Services 

Program (SSP) Evaluation’, which 

proposes to: (1) Assess and monitor SSP 

operational characteristics and services, 

client characteristics and drug use 

patterns, client satisfaction, funding 

resources, community relations, and key 

operational and programmatic successes 

and challenges and (2) support timely 

analysis and dissemination of national 

program evaluation survey findings. 

DATES: CDC must receive written 

comments on or before April 26, 2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0012 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

5. Assess information collection costs. 

Proposed Project 

National Syringe Services Program 

(SSP) Evaluation—New—National 

Center for HIV/AIDS, Viral Hepatitis, 

STD, and TB Prevention (NCHHSTP), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

The primary purpose of the National 

Syringe Services Program (SSP) 

Evaluation is to strengthen and improve 

the capacity of SSPs to conduct regular 

monitoring and evaluation to ensure 

that comprehensive prevention services 

are provided to meet the needs of 

people who inject drugs (PWID) and 

reduce infectious disease and other 

harms related to intravenous drug use 

(IDU). The project will invite the 

participation of all SSPs that are listed 

in a publicly available directory of all 

known SSPs in the United States 

maintained by the North American 

Syringe Exchange Network (NASEN; 

https://nasen.org). SSPs will be sent a 

letter of invitation to participate in a 35- 

minute program survey. Participating 

programs will have the option of 

completing the survey via different 

modalities to enhance feasibility and 

comfort in completing the survey, for 

example via the Research Electronic 

Data Capture (REDCap) or a similarly 

secure web-based application. Other 

modalities for survey administration 

will include a coordinated telephone or 

videoconferencing interview. SSPs will 

be sent reminder letters for an 

approximately three-month data 

collection period. SSPs that do not 

respond to prior reminders will be sent 

one final reminder, and if the SSP still 

does not want to participate, one 

(optional) question on why the SSP did 

not complete the survey will be offered. 

The survey will include questions on 

operational characteristics and services, 

client characteristics and drug use 

patterns, client satisfaction, funding 

resources, community relations, and key 

operational successes and challenges. 

Approximately 400 SSPs will be able to